reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
2CmO2 + H2 → Cm2O3 + H2O Also, a number of ternary oxides of the type M(II)CmO3 are known, where M stands for a divalent metal, such as barium. Thermal oxidation of trace quantities of curium hydride (CmH2–3) has been reported to give a volatile form of CmO2 and the volatile trioxide CmO3, one of two known examples of the very rare +6 state for curium. Another observed species was reported to behave similar to a supposed plutonium tetroxide and was tentatively characterized as CmO4, with curium in the extremely rare +8 state; but new experiments seem to indicate that CmO4 does not exist, and have cast doubt on the existence of PuO4 as well.
==== Tetsu ==== Tekkan Aira (姶良 鉄幹, Aira Tekkan), also known as "Tetsu" (テツ), is an elite officer from S.P.D.'s Tokkyou (特キョウ, Tokkyō) division, serving as the white-colored Deka Break (デカブレイク, Deka Bureiku), who was sent to Earth to delete the Hells Siblings and staying on Earth to help the Earth unit. As a child, Tetsu's parents were killed by an Alienizer named Genio, before Tetsu was taken off-world and raised by S.P.D. Due in part to this, he is initially distant from the other Dekarangers, but eventually befriends them. In battle, Tetsu is a practitioner of the fighting style Justice Fist Accel Blow (正拳アクセルブロー, Seiken Akuseru Burō), a martial art that all Tokkyou officers train in to better handle their equipment and battle particularly deadly Alienizers. Unlike the primary Dekarangers, he wields the Bracerottle (ブレスロットル, Buresurottoru), which functions as an SP License, can double as a life-support system and a fire extinguisher, and allows him to perform a variety of specialized Fist (フィスト, Fisuto) attacks. He also rides the Machine Boxer (マシンボクサー, Mashin Bokusā) police motorcycle. During the events of the crossover film GoGo Sentai Boukenger vs. Super Sentai, Tetsu, among other veteran Sentai warriors, is recruited by Boukenger member Eiji Takaoka to help him rescue his allies and defeat the Time Demon, Chronos. In the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Tetsu becomes the new head of S.P.D.'s Earth unit, following Doggie Kruger being framed for murder, and assists in clearing his predecessor's name.
This is a list of episodes for Traders a Canadian television drama series, which was broadcast on Global Television Network from 1996 to 2000. The show was set in a Bay Street investment bank, Gardner Ross. Bruce Gray and Sonja Smits starred as the firm's senior partners, Adam Cunningham and Sally Ross. The cast also included Patrick McKenna, David Cubitt, Rick Roberts, Chris Leavins, Gabriel Hogan, David Hewlett, Peter Stebbings and Alex Carter.
Sources: en.wikipedia.org
==== Nations ==== Bahrain: Bahrain called for a lasting solution that will prevent Iran from getting nuclear weapons or from doing things that could destabilize the region. France: President Emmanuel Macron said that he remained concerned about the "critical" situation in Lebanon, after Israel continued its strikes and occupation of southern Lebanon after the ceasefire, stating that this "cannot be a long-term solution." France also looked forward to securing shipping through the Strait of Hormuz. Germany: Germany urged Iran to respect the ceasefire and to allow ships to cross the Strait of Hormuz safely and freely. They also urged Iran to take advantage of the opportunity for negotiations. India: The Indian Ministry for External Affairs welcomed the US-Iran ceasefire agreement and called for an early end to the conflict for "unimpeded" trade flow through the Strait of Hormuz. Iraq: The Iraqi oil ministry said on 9 April that no Iraqi ships had crossed the Strait since the ceasefire came into effect. Kuwait: Kuwait's foreign ministry urged Iran and its "proxies, including factions, militias, and armed groups loyal to it" to cease all hostilities against Gulf Arab states. Qatar: Qatar's foreign ministry considered the ceasefire "an initial step toward de-escalation" and hoped Iran would "cease all hostile acts and practices that undermine regional stability." Russia: Russia welcomed the ceasefire and expressed hope that the United States would be able to resume peace negotiations in the Russo-Ukrainian war.
On 21 March, Japanese ambassador to Brazil Teiji Hayashi confirmed that prime minister Fumio Kishida would invite president Lula to the 49th G7 summit to be held from 19 to 21 May 2023 in Hiroshima, which formally took place on 6 April. In May 2023, Kishida met with Lula and announced that Japan was starting procedures to grant Brazilians travel visa exemptions and was opening a ¥30 billion line of credit to support health companies and other businesses in Brazil through Japan International Cooperation Agency (JICA). Lula said Brazil and Japan need to further develop their commercial, cultural, political and scientific relationship adding that "we have cultural bonds with Japan and a great Japanese-Brazilian community". Both leaders also discussed education, climate change, development and peace.
==== Non-peptide ==== CA7 – among smallest-known oxytocin receptor agonists; considerable selectivity over the vasopressin V1A receptor KNX-200 (KNX200) – series; chemical structure(s) not yet disclosed LIT-001 — improved social deficits in mice; non-selective over vasopressin receptors LIT-002 – extremely potent; improved social deficits in mice; non-selective over vasopressin receptors TC OT 39 – non-selective over vasopressin receptors WAY-267,464 – anxiolytic in mice; possibly non-selective over vasopressin receptors WJ0679 – among smallest-known oxytocin receptor agonists; produces prosocial effects in rodents
== Selected publications == Books Identification and Application of Phenotypic and Molecular Markers for Abiotic Stress Tolerance in Soybean, Berhanu Amsalu Fenta, Belen Marquez Garcia, Christine H. Foyer, Karl J. Kunert, Magdeleen DuPlessis, Urte Schluter: 2011. INTECH Open Access Publisher: ISBN 978-953-307-721-5 A New Era in Plant Metabolism Research Reveals a Bright Future for Bio-fortification and Human Nutrition, Christine H Foyer, Dean Dellapenna, Dominique Van der Straeten: 2006 Plant Carbon-nitrogen Interactions from Rhizosphere to Plant, Caroline Bowsher, Christine H Foyer, Society for Experimental Biology: Oxford University Press: 2004. Molecular Physiology: Engineering Crops for Hostile Environments, Martin A Parry, Christine H Foyer, Brian Forde: Oxford University Press: 2000. ISBN Causes of Photooxidative Stress and Amelioration of Defense Systems in Plants, Christine H Foyer, Philip M Mullineaux: CRC Press: 1994. ISBN 978-0-8493-5443-4 Photosynthesis, Christine H Foyer, Kreiger Publishing Co.: 1991 ISBN 978-0-89464-506-8 Research articles Foyer, Christine H.; Halliwell, Barry (1976). "The presence of glutathione and glutathione reductase in chloroplasts: a proposed role in ascorbic acid metabolism". Planta. 133 (1): 21–25. doi:10.1007/BF00386001. PMID 24425174. S2CID 27896738.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.